The acquisition of qGenomics’ expertise in carrier screening, arrays, and rare disease diagnostics expands Veritas’ service portfolio and reinforces its footprint in clinical genomics.

Veritas Genetics, a global leader in medical genomics, announces the acquisition of qGenomics, a market leader in carrier screening and arrays. With this acquisition, Veritas integrates the company’s robust capabilities and scientific expertise, enabling the further expansion of its perinatal and clinical genetics offering. It also paves the way for the launch of Veritas’ own carrier screening, completing its comprehensive portfolio for healthcare professionals and patients alike.

Founded in 2008 by Lluis Armengol, Xavier Estivill and Luis Pérez Jurado, as a spin-off of the Centre de Regulació Genòmica (CRG) and Universitat Pompeu Fabra (UPF), qGenomics has been a scientific and technological benchmark in genomics for over 15 years supported with investments by clinical and diagnostic leaders Grupo Dexeus Mujer and Laboratorio Echevarne. With a clear mission to bring research closer to the clinic, the company has led national and international efforts in the diagnosis of rare diseases and chromosomal disorders, serving both the public and private sectors.

qGenomics’ founding partners and investors have reinvested into Paulus Holdings, the holding vehicle of Veritas Genetics.

Javier de Echevarría, CEO of Veritas Genetics, stated: “With this acquisition, Veritas integrates qGenomics’ robust capabilities in technologies such as arrays and carrier screening, enabling the expansion of our perinatal and clinical genetics offering. It also paves the way for the launch of qCarrier across Veritas later in 2025, completing a comprehensive portfolio that supports healthcare professionals and empowers patients across every stage of life. We are proud to welcome the qGenomics team, combining scientific excellence with a shared mission to advance genomic medicine.”

Lluis Armengol, co-founder and CEO of qQenomics added “joining Veritas Genetics is a natural evolution in our journey. It allows us to amplify our scientific impact, strengthen our diagnostic capabilities, and continue serving patients and healthcare professionals with the same rigor and commitment that has defined us since day one”. Lluis Armengol will remain in the Group and has been appointed Chief Scientific Officer of Veritas Genetics.

An Integrated, Scientific, and Scalable Model

The integration of qGenomics into Veritas will enhance the Group’s capabilities in rare disease diagnostics, while also enabling the internal development of carrier screening solutions for its markets—completing a robust perinatal portfolio.

This acquisition also reflects Veritas Genetics continued commitment to building a leading ecosystem of genomic-driven healthcare services.

This acquisition follows the acquisition of NIMGenetics in December 2024, a company with a complementary client base and strong presence in clinical genetic diagnostics. Both acquisitions support the same strategic goal: delivering a more seamless, efficient experience under a single brand: Veritas Genetics.

About Veritas Genetics

Veritas Genetics is a global leader in the field of genomics. We specialize in Whole Genome Sequencing (WGS) and its clinical interpretation, which allows us to provide a detailed view of a patient’s genetic information for both preventive and diagnostic purposes.

Our clinical genomics platform is the foundation of our personalized medicine services, which are tailored to the individual needs of people throughout all stages of life.

Through a constant commitment to innovation and accessibility, we are working to transform the way healthcare is understood and managed worldwide.

About qGenomics

qGenomics is a diagnostic laboratory specialized in the genetics of rare diseases, array analysis, and carrier screening. Founded in 2008 as a spin-off from the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF). qGenomics has played a key role in numerous research projects and diagnostic programs in collaboration with hospitals, universities, and genetics centers, contributing to the development and implementation of Clinical Genetics and Genomic Medicine. It is a reference in technologies such as chromosomal microarrays and carrier screening.